We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

83 hedge funds and large institutions have $56.7M invested in Relmada Therapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

26% more capital invested

Capital invested by funds: $45M → $56.7M (+$11.8M)

4.25% less ownership

Funds ownership: 49.8% → 45.55% (-4.3%)

5% less funds holding

Funds holding: 87 → 83 (-4)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

79% less call options, than puts

Call options by funds: $296K | Put options by funds: $1.41M

Holders
83
Holders Change
-4
Holders Change %
-4.6%
% of All Funds
1.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
27
Reduced
19
Closed
16
Calls
$296K
Puts
$1.41M
Net Calls
-$1.12M
Net Calls Change
-$342K

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$2.51M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$740K
3
Deutsche Bank
Deutsche Bank
Germany
+$651K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$485K
5
Marshall Wace
Marshall Wace
United Kingdom
+$455K

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$6.4M
2
DTC
Deep Track Capital
Connecticut
-$2.35M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$478K
4
SSA
Schonfeld Strategic Advisors
New York
-$328K
5
Voloridge Investment Management
Voloridge Investment Management
Florida
-$274K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$604K – – –
UBS Group
27
UBS Group
Switzerland
$521K +$124 +42 +0%
State Street
28
State Street
Massachusetts
$477K – – –
VPC
29
Vestal Point Capital
New York
$476K +$340K +115,000 New
MOS
30
MGO One Seven
Ohio
$414K – – –
SCM
31
Silverarc Capital Management
Massachusetts
$414K – – –
Federated Hermes
32
Federated Hermes
Pennsylvania
$413K -$42.5K -14,363 -13%
Northern Trust
33
Northern Trust
Illinois
$399K +$146K +49,165 +104%
Fidelity Investments
34
Fidelity Investments
Massachusetts
$348K -$391 -132 -0.2%
AW
35
Apricus Wealth
South Carolina
$326K +$4.44K +1,500 +2%
AI
36
AdvisorShares Investments
Maryland
$309K -$113K -38,242 -34%
Dimensional Fund Advisors
37
Dimensional Fund Advisors
Texas
$305K – – –
Squarepoint
38
Squarepoint
New York
$304K +$119K +40,337 +122%
Citigroup
39
Citigroup
New York
$303K -$78.2K -26,400 -27%
Connor, Clark & Lunn Investment Management (CC&L)
40
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$253K -$77K -25,992 -30%
ACM
41
ADAR1 Capital Management
Texas
$243K +$174K +58,601 New
Simplex Trading
42
Simplex Trading
Illinois
$231K +$52.3K +17,664 +46%
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$179K +$39.5K +13,354 +45%
IC
44
Ikarian Capital
Texas
$167K – – –
SEI Investments
45
SEI Investments
Pennsylvania
$150K +$266 +90 +0.2%
MHC
46
Meyer Handelman Company
New York
$135K – – –
AG
47
AlTi Global
New York
$131K +$93.9K +31,715 New
HKAM
48
Horizon Kinetics Asset Management
New York
$124K +$88.8K +30,000 New
PAM
49
Pegasus Asset Management
New York
$112K – – –
XT
50
XTX Topco
Cayman Islands
$91.1K +$65.2K +22,009 New
1
2
3 4

RLMD Hedge Fund Activity: Q4 2023 in Review

83 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2023, worth a combined $56.7M — up 26% from $45M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of RLMD and 14 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 27 added.

The largest buyer was Opaleye Management, adding an estimated $2.51M. The largest seller was RTW Investments, exiting entirely with an estimated $6.4M sold.

  • 83 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2023, down from 87 in Q3 2023.
  • Funds reported $56.7M of Relmada Therapeutics stock for Q4 2023, up 26% quarter-over-quarter.
  • 14 funds opened new Relmada Therapeutics positions in Q4 2023 and 16 closed out, a net change of -2 holders.
  • The largest Relmada Therapeutics buyer in Q4 2023 was Opaleye Management, an estimated $2.51M added.
  • The largest Relmada Therapeutics seller in Q4 2023 was RTW Investments, an estimated $6.4M sold.

Based on aggregated 13F filings for Q4 2023.